Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 3.5Cr |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.21% | -4.63% | +55.34% | +71.32% | 6.9TCr | |
| +0.11% | +4.26% | +6.78% | +61.57% | 5.31TCr | |
| -0.20% | +5.24% | +9.85% | +41.33% | 5.08TCr | |
| +3.45% | +4.70% | +33.44% | +35.96% | 4.46TCr | |
| -2.20% | +0.61% | +281.88% | +532.76% | 4.06TCr | |
| +6.43% | +6.84% | +18.32% | +109.23% | 4.25TCr | |
| +1.28% | +1.39% | +11.69% | +45.10% | 3.09TCr | |
| -0.90% | -10.49% | +31.48% | -1.63% | 2.54TCr | |
| +1.74% | -2.02% | -13.55% | -12.92% | 2.27TCr | |
| Average | +1.10% | +1.56% | +48.36% | +98.08% | 4.22TCr | |
| Weighted average by Cap. | +1.07% | +2.33% | +50.67% | +103.28% |
